Topic
Medicines used to treat obesity and related metabolic disease, including incretin-based drugs that act on GLP-1 and GIP hormone receptors.
Prime Therapeutics' study, reported in June 2025, found 8.1% of 5,780 non-diabetic GLP-1 obesity patients stayed on therapy for all three years. The cohort began in 2021 and early 2022 amid shortages, a weak base for projecting revenue or spend on patients starting after the shortages.
Reality
Eli Lilly's 367-person trial found the top dose of tirzepatide plus eloralintide cut body weight 23.3%, against 14.8% on tirzepatide alone. Dropout ran far higher on the combination, so nobody has yet measured how much of that gain holds across everyone prescribed the pair.
Reality
AriBio's October Phase 3 readout for AR1001 decides whether Fosun Pharma adds $80 million to the $60 million option fee it paid in May. Among the Korean biotech events due that month, it is the one that ties a partner's cash directly to trial data.
Reality
Eli Lilly's retatrutide cut body weight by more than 20% on average at its top dose in an 80-week phase 3 trial of 1,152 people with type 2 diabetes. Lilly calls that a first for the field, and it gives the four- and five-receptor drugs now in development a figure to beat in patients with diabetes.
Reality
University of Barcelona researchers found that tirzepatide activated calorie-burning brown fat in obese mice eating the same amount as untreated controls. The result points to an effect on metabolism beyond appetite that has not yet been tested in humans.
Reality